Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, develops treatments for people suffering from acute cannabinoid intoxication and substance addiction. The Company's lead product candidate, ANEB-001, is a potent, small molecule cannabinoid receptor antagonist designed to address the unmet medical need for a specific antidote for cannabinoid overdose. The company was incorporated in 2020 and is based in Lakeway, TX.
Name / Ticker | Price | Zen Rating |
---|---|---|
$7.92 | A | |
$22.81 | A | |
$40.74 | A |